Kubo Shiyuuji Department
Hyogo Medical University(Laboratory/Facility)
, Institute for Advanced Medical Sciences
Position
■ Journal
1.
Original article
Molecular targeting of hepatocyte growth factor by an antagonist, NK4, in the treatment of rheumatoid arthritis. 2013/07
2.
Original article
FK506 induces endothelial dysfunction through attenuation of Akt and ERK1/2 independently of calcineurin inhibition and the caspase pathway. 2013/09
3.
Original article
Enhanced antitumor efficacy of fiber-modified, midkine promoter-regulated oncolytic adenovirus in human malignant mesothelioma. 2013/11
4.
Original article
Highly efficient tumor transduction and antitumor efficacy in experimental human malignant mesothelioma using replicating gibbon ape leukemia virus. 2013/12
5.
Original article
Oncolytic virotherapy for osteosarcoma using midkine promoter-regulated adenoviruses. 2014/02
6.
Original article
Haploinsufficiency of the c-myc transcriptional repressor FIR, as a dominant negative-alternative splicing model, promoted p53-dependent T-cell acute lymphoblastic leukemia progression by activating Notch1. 2015/03
7.
Original article
Brain vascular pericytes following ischemia have multipotential stem cell activity to differentiate into neural and vascular lineage cells. 2015/06
8.
Original article
Brain vascular pericytes following ischemia have multipotential stem cell activity to differentiate into neural and vascular lineage cells. 2015/06
9.
Original article
Combinatorial anti-angiogenic gene therapy in a human malignant mesothelioma model. 2015/08
10.
Original article
Adenovirus-mediated FIR demonstrated TP53-independent cell-killing effect and enhanced antitumor activity of carbon-ion beams. 2016/01
11.
Original article
Whole cell vaccination using immunogenic cell death by an oncolytic adenovirus is effective against a colorectal cancer model. 2016/12
12.
Original article
A patient-derived xenograft and a cell line derived from it form a useful preclinical model for small bowel adenocarcinoma 2020/05
13.
Original article
Assessment of circulating microRNA specific for patients with familial adenomatous polyposis 2021/05
Hybrid vectors as trojan horses; adventure with adenovirus for successful gene therapy. (Oral presentation,Special/Invited Lecture) 2013/04/15
2.
Anti-Tumor effects of ad-p53 on INK4A/ARF-defective mesothelioma are influenced positively by small G protein inhibitors but negative by heat shock protein 90 inhibitors (Poster presentation,General Lecture) 2013/05/16
3.
Comparative evaluation of the antitumor activity of anti-anqioqeni proteins delivered by lentivirus vector in humaan maliqnant mesothelioma model (Poster presentation,General Lecture) 2013/05/16
4.
Development of dual targeted oncolytic adenovirus for human malignant mesothelioma (Poster presentation,General Lecture) 2013/05/18
5.
Adventure with viruses toward the success of gene therapy against malignant mesothelioma (Oral presentation,Special/Invited Lecture) 2013/06/04
6.
Bisphosphonates and Nutlin-3a augments cytotoxicity induced by adenovirally expressed p53 in p53 wild-type mesothelioma (Oral presentation,General Lecture) 2013/07/05
7.
Midkine promoter-driven oncolytic adenovirus with adenovirus 35 fiber modification achieves enhanced transduction of human osteosarcoma cells (Oral presentation,General Lecture) 2013/07/06
8.
Biological roles of deletion of PBRM1 and BAP1 in malignant mesotheliomas (Oral presentation,General Lecture) 2013/10/03
9.
Bisphosphonates produce cytotoxic effects on mesothelioma through inhibiting topoisomerase II and rab functions (Oral presentation,General Lecture) 2013/10/04
10.
Dual targeted adenovirus for oncolytic virotherapy in experimental human osteosarcoma (Oral presentation,General Lecture) 2013/10/05
11.
SF3B1 inhibitor as a novel molecular targeted drug candidate for colorectal cancer (Oral presentation,General Lecture) 2013/10/05
12.
SF3B1 inhibitor as a novel molecular targeted drug candidate for colorectal cancer (Oral presentation,General Lecture) 2013/10/05
13.
Prodrug activator gene therapy using replicating gibbon ape leukemia virus in an experimental model of human malignant mesothelioma (Oral presentation,General Lecture) 2014/08/06
14.
Combination of nutlin-3a and Hsp90 inhibitors produces p53-dependent synergism on human mesothelioma cells (Poster presentation,General Lecture) 2014/09/25
15.
Alternative splicing of c-myc transcriptional repressor, FIR,contributes T-ALL by c-Myc activation (Oral presentation,General Lecture) 2014/09/26
16.
FIR splicing as a molecular sensor for bleomycin-induced DNA damage response pathway (Oral presentation,General Lecture) 2014/09/26
17.
Rare germline variants of transcription regulator genes in malignant mesothelioma (Poster presentation,General Lecture) 2014/09/27
18.
SF3B1 is a novel molecular target for induction of synthetic lethality with the other anticancer drug. (Oral presentation,General Lecture) 2014/09/27
19.
Suicide gene therapy by replicating gibbon ape leukemia virus in an experimental model of human malignant mesothelioma (Oral presentation,General Lecture) 2014/09/27
20.
Transduced p53 enhances cytotoxic effects achieved with oncolytic adenoviruses on pancreatic carcinoma cells (Oral presentation,General Lecture) 2014/09/27
21.
Comparative evaluation of suicide gene therapy using retroviral peplicating vectors in an experimental model of human malignant mesothelioma (Poster presentation,General Lecture) 2014/10/21
22.
Enhanced transduction and antitumor efficiency of fiber-modified,midkine promoter-regulated oncolytic adenovirus in human malignant mesothelioma (Poster presentation,General Lecture) 2014/10/21
23.
Educational program on human genetics and clinical genetics for medical students (Oral presentation,General Lecture) 2014/11/22
Brain pericytes following ischemia acquire neural phenotypes in a mesenchymal-epithelial transition like manner (Oral presentation,General Lecture) 2015/07/30
26.
The CiTi Japan Program introduced into undergraduate medical education (Oral presentation,General Lecture) 2016/04/04
27.
Combinatorial anti-angiogenic gene therapy in a human malignant mesothelioma model (Poster presentation,General Lecture) 2016/05/04
28.
Customization of virotherapy with replicating retroviral replicating vectors on the basis of cellular receptor expression profiles. (General Lecture) 2016/07
29.
Customization of virotherapy with retroviral replicating vectors on the basis of cellular receptor expression profiles. (Poster presentation,General Lecture) 2016/10
30.
A MDMX inhibitor produces cytotoxicity in a p53-independentmanner but achieves synergistic action with MDM2 inhibitors (Oral presentation,General Lecture) 2016/10/07
31.
Prodrug Activator Gene Therapy Using Retroviral Replicating Vectors in an Experimental Model of Human Osteosarcoma (Poster presentation,General Lecture) 2017/05/10
32.
An Inhibitor for the MDM2-p53 Interaction Produces Synergistic Cytotoxicity with Oncolytic Adenoviruses on Mesothelioma with Wild-Type p53 Genotype (Poster presentation,General Lecture) 2017/05/12
33.
A MDM2 inhibitor augments cytotoxicity of oncolytic adenoviruses defective of E1B 55kDa molecules through enhancing DNA damages and apoptosis in mesothelioma (Oral presentation,General Lecture) 2017/07/20
A Weel kinase inhibitor increases apoptosis of replication-competent adenoviruses through induction of mitotic catastrophe and enhancement of viral replications (Oral presentation,General Lecture) 2017/07/22
36.
A MDM2 inhibitor achieves synergistic cytotoxicity with oncolytic adenoviruses on mesothelioma with the wild-type p53 (Oral presentation,General Lecture) 2017/09/30
Peritoneal dissemination of rectal cancer cells from patient-derived. (Poster presentation,General Lecture) 2019/09/26
39.
FOXQ1 expression is associated and K-RAS/BRAF mutation status in colorectal cancer. (Poster presentation,General Lecture) 2019/09/28
40.
Gap junction protein alpha 1-derived effects against brain microglia differ among the interacted cell types, including endothelial cells, astrocytes, and pericytes (Poster presentation,General Lecture) 2023/08